UCB, a Belgian pharmaceutical company, today presented to a dermatology conference data that it had announced last July, showing that their experimental treatment Cimzia (certolizumab pegol, CDP870), which has shown effectiveness against Crohn’s disease, also showed strong results in a Phase Two trial for moderate to severe psoriasis.
You can learn more about Cimzia and other new treatments being developed for psoriasis in our newly-updated clinical trials report.
Category: Uncategorized
